Regulation of equine lymphocyte beta-adrenoceptors under the influence of clenbuterol and dexamethasone.
Authors: Abraham G, Brodde O E, Ungemach F R
Journal: Equine veterinary journal
Summary
# Editorial Summary Prolonged clenbuterol administration—a beta-2 agonist commonly used to treat equine airway obstruction—causes desensitisation of lymphocyte beta-2 adrenoceptors, with receptor density declining by 30–40% and associated impairment of cellular cAMP signalling responses following a 12-day treatment course at 1.6 μg/kg/day. This phenomenon raises important questions about the efficacy of extended clenbuterol therapy, as receptor downregulation potentially undermines the drug's therapeutic benefit over time. Abraham and colleagues demonstrated that concurrent or sequential dexamethasone administration (0.1 mg/kg/day) substantially mitigates this desensitisation: when given simultaneously with clenbuterol, dexamethasone prevented receptor downregulation entirely, whilst post-treatment dexamethasone accelerated receptor recovery within 24 hours and paradoxically upregulated receptors to approximately twofold baseline levels. For practitioners managing chronic equine obstructive pulmonary disease, these findings suggest that combining clenbuterol with short courses of glucocorticoids may preserve bronchodilator responsiveness and prevent the loss of therapeutic efficacy that occurs with clenbuterol monotherapy, though further clinical investigation of this combination approach in COPD-affected horses would be warranted to establish optimal dosing protocols and clinical outcomes.
Read the full abstract on PubMed
Practical Takeaways
- •Combined clenbuterol and dexamethasone therapy may be more effective than clenbuterol alone for equine COPD by preventing beta2-adrenoceptor desensitization that develops with prolonged beta2-agonist use
- •If clenbuterol monotherapy has lost efficacy, adding dexamethasone can rapidly restore lymphocyte beta2-adrenergic responsiveness within 24 hours rather than waiting 4 days for natural recovery
- •Glucocorticoid co-therapy addresses a fundamental pharmacological limitation of sustained beta2-agonist therapy in horses with chronic respiratory disease
Key Findings
- •Clenbuterol treatment decreased lymphocyte beta2-adrenoceptor binding sites by 30-40% and reduced cAMP responsiveness, with recovery to baseline over 4 days after withdrawal
- •Dexamethasone administered after clenbuterol withdrawal restored beta2-adrenoceptor density and cAMP response within 24 hours and increased receptors 2-fold above pretreatment levels by day 3
- •Simultaneous administration of dexamethasone completely prevented clenbuterol-induced desensitization of beta2-adrenoceptors
- •No changes in receptor affinity (dissociation constant) were observed across any treatment condition